ABCG1

ABCG1 rs57137919 — The Promoter Variant That Rewrites the Macrophage–Cholesterol Equation

Deep inside arterial walls, macrophages perform one of the most critical housekeeping tasks in
cardiovascular biology: absorbing excess cholesterol from the surrounding tissue and offloading it
to high-density lipoprotein (HDL) particles for return to the liver. This reverse cholesterol
transport pathway — the body's primary mechanism for clearing arterial cholesterol — depends on the
ABCG1 transporter | ATP-binding cassette subfamily G member 1, a membrane protein that pumps
cholesterol and phospholipids from macrophage cell membranes onto mature HDL particles. When ABCG1 is disrupted, macrophages loaded with
cholesterol cannot offload their cargo efficiently. They accumulate cholesterol, become foam cells,
undergo accelerated apoptosis, and contribute to the necrotic core of atherosclerotic plaques.

The rs57137919 variant sits in the promoter region of ABCG1 (described as -367G>A in the original
literature, consistent with its position upstream of key ABCG1 transcripts on chromosome 21).
The G allele at this position is the GRCh38 reference and the population-major allele (~86%
globally). It is associated with higher CAD risk in population studies — not because G is pathogenic,
but because the less-common A allele confers protection through mechanisms that appear to dominate
the macrophage impairment seen in cell studies.

The Mechanism

The rs57137919 G>A substitution reduces the ability of regulatory proteins to bind the ABCG1
promoter region. Luciferase reporter assays confirmed
that the A allele impairs promoter-driven transcription, leading to lower ABCG1 mRNA and protein
expression in macrophages. At the cellular level, this has measurable consequences: macrophages
from A/A donors show 23% less ABCG1-mediated cholesterol efflux and a 2-fold increase in
cholesterol-induced apoptosis compared to G/G
macrophages, with significant upregulation of the pro-apoptotic genes Bok and Bid.

Yet at the population level, A allele carriers have better cardiovascular outcomes. The most
likely explanation is that ABCG1 also regulates systemic lipoprotein metabolism in ways that
benefit the overall lipid profile: A allele carriers show higher HDL-C and lower LDL-C in multiple
Chinese cohort studies. The net effect — better circulating lipid profile — appears to outweigh the
macrophage-level efflux impairment in population cardiovascular endpoints. This makes rs57137919
a compelling example of how a single variant can have opposing biological effects at the cellular
and systemic levels simultaneously.

The Evidence

The foundational study is Xu et al. 2011 (Atherosclerosis),
a case-control study of 1,021 CAD patients and 1,013 controls in a Chinese Han population. A allele
carriers had an adjusted OR of 0.73 (p=0.033) for CAD and 0.65 (p=0.014) for myocardial infarction.
Among those with CAD, A allele carriers showed less severe angiographic disease (multi-vessel vs
single-vessel OR=0.40, p=0.005). The same study confirmed with luciferase assays that the A allele
reduces ABCG1 promoter function, establishing the functional basis for the observed association.

The mechanistic detail was expanded by Liu et al. 2014 (PLoS One),
which isolated macrophages from human donors stratified by rs57137919 genotype and measured
cholesterol efflux and apoptosis directly. G/G macrophages showed the highest efflux capacity;
A/A macrophages showed 23% lower efflux and twice the rate of apoptosis when loaded with
cholesterol. This cellular impairment is real and biologically significant — it would be expected
to accelerate plaque formation in isolation.

On lipid profiles, Wang et al. 2020 (Ann Vasc Surg)
documented that GA and AA carriers have significantly higher HDL-C (p=0.021) and lower LDL-C
(p=0.017) than GG individuals in a Chinese Han cohort. The connection to stroke was confirmed by
Yang et al. 2022 (Gene) — the AA genotype was
significantly less common in stroke patients (4.6% vs 13.3% in controls, p=0.030) and associated
with the lowest LDL-C levels. In Li et al. 2015,
the protective effect was particularly evident in hypertriglyceridemic subjects.

Note that all published studies to date have been conducted in East Asian populations (primarily
Chinese Han), which limits direct generalizability to European or African ancestry groups. The
biological mechanism is expected to be conserved, but effect sizes in other populations require
separate study.

Practical Actions

For GG homozygotes (~74% of people globally): ABCG1 is expressed at full baseline levels in
macrophages — reverse cholesterol transport operates without the promoter impairment carried by A
allele carriers. The trade-off is that population studies show GG individuals have modestly higher
CAD and stroke risk compared to A carriers, driven by less favorable average lipid profiles (lower
HDL-C, higher LDL-C). Supporting ABCG1 function and HDL-mediated cholesterol clearance through
targeted dietary and lifestyle choices is worthwhile.

For GA heterozygotes (~24%): one A allele partially reduces ABCG1 expression, producing an
intermediate effect on both macrophage efflux and lipid profile. HDL-C tends to be mildly higher
and LDL-C modestly lower than GG. Monitoring the lipid profile — especially HDL-C and triglycerides
together — gives a more complete picture.

For AA homozygotes (~2%): two A alleles produce the largest reduction in ABCG1 expression,
the most impaired macrophage cholesterol efflux, and the greatest elevation of macrophage apoptosis.
Paradoxically, these individuals also tend to have the most favorable circulating lipid profiles
(highest HDL-C, lowest LDL-C) and show the greatest population-level protection from CAD and
stroke. The cellular-level macrophage impairment is real and may become clinically relevant under
conditions of high dietary cholesterol or pro-inflammatory stress that overwhelms the protective
lipid profile advantage.

Interactions

ABCG1 works in concert with ABCA1 in macrophage cholesterol efflux — ABCA1 mediates initial
transfer of cholesterol to lipid-poor apoA-I (forming nascent HDL), while ABCG1 loads cholesterol
onto mature spherical HDL particles. Variants in ABCA1 (rs4149338) have been studied alongside
rs57137919 in stroke research, with opposing directions: ABCA1 variants associated with increased
stroke risk while ABCG1 rs57137919 A allele showed protection. The combined effect of ABCG1 and
ABCA1 variants on macrophage cholesterol efflux capacity is a candidate for compound action, given
that both transporters act sequentially in the same pathway.

The protective effect of the A allele is particularly pronounced in hypertriglyceridemic
individuals (Li et al. 2015), suggesting the rs57137919 effect may interact with triglyceride
metabolism. ABCG1 participates in VLDL processing and lipoprotein particle remodeling, providing
a mechanistic link between this promoter variant and triglyceride pathways — placing it at the
intersection of macrophage biology and fatty acid metabolism.